Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANAPTYSBIO, INCANAB · Entity 4640 | Director | February 08, 2019 | February 11, 2019 |
| Blueprint Medicines CorpBPMC · Entity 77326 | Director | June 12, 2024 | June 14, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANAPTYSBIO, INC
Report date February 08, 2019 · Filed February 11, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $68.89 · Expires 2029-02-07 | Direct | 6,000 |
Reported balance
After 2019-02-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-02-08 · Grant · Acquired 6,000 · Balance 6,000 F1: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on March 8, 2019, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on March 8, 2019, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date.
Blueprint Medicines Corp
Report date June 12, 2024 · Filed June 14, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 58,026 |
Reported balance
After 2024-06-12 transaction · row 1
1 source rowRow 1 · 2024-06-12 · Grant · Acquired 2,242 · Balance 58,026 F1: The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) June 12, 2025 and (ii) the next annual meeting of the Issuer's stockholders. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $106.14 · Expires 2034-06-12 | Direct | 4,570 |
Reported balance
After 2024-06-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-06-12 · Grant · Acquired 4,570 · Balance 4,570 F2: This option vests with respect to 100% of the shares underlying the option on the earlier of (i) June 12, 2025 and (ii) the next annual meeting of the Issuer's stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) June 12, 2025 and (ii) the next annual meeting of the Issuer's stockholders. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2: This option vests with respect to 100% of the shares underlying the option on the earlier of (i) June 12, 2025 and (ii) the next annual meeting of the Issuer's stockholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 21, 2017 Filed Jun 23, 2017 16:25 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | GrantStock Option (Right to Buy) · Derivative | 10,909 | $0.00 Strike: $46.02 | $0.00 |
DisclosureSEC source: 0001179110-17-009521 · edgar.xml · derivative · entry 1 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,818 Underlying: Common Stock · 10,909 shares Expires 2027-06-21 F1 · derivative.exercise_date: This option vests with respect to 100% of the shares underlying the option on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 21, 2018. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 17:37 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 1,400 | $39.72 | $55,608.00 |
DisclosureSEC source: 0001179110-17-004740 · edgar.xml · nonDerivative · entry 2 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,727 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.70 to $39.76 per share. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 17:37 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 68,600 | $40.06 | $2,748,116.00 |
DisclosureSEC source: 0001179110-17-004740 · edgar.xml · nonDerivative · entry 1 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,127 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.80 to $40.78 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 23:54 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantDirector Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $24.60 | $0.00 |
DisclosureSEC source: 0001209191-17-015460 · doc4.xml · derivative · entry 1 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-02-23 F1 · derivative.exercise_date: The stock option vests and becomes fully exercisable on February 24, 2018. Read SEC document |
| January 31, 2017 Filed Jan 31, 2017 21:49 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | ConversionSeries D Preferred Stock · Derivative | 67,345 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-006404 · doc4.xml · derivative · entry 5 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 67,345 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated. F1 · derivative.exercise_date: In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated. F1 · derivative.expiration_date: In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated. Read SEC document |
| January 31, 2017 Filed Jan 31, 2017 21:49 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | ConversionSeries C Preferred Stock · Derivative | 55,403 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-006404 · doc4.xml · derivative · entry 4 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 55,403 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated. F1 · derivative.exercise_date: In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated. F1 · derivative.expiration_date: In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated. Read SEC document |
| January 31, 2017 Filed Jan 31, 2017 21:49 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | ConversionSeries B Preferred Stock · Derivative | 80,877 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-006404 · doc4.xml · derivative · entry 3 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 80,877 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated. F1 · derivative.exercise_date: In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated. F1 · derivative.expiration_date: In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated. Read SEC document |
| January 31, 2017 Filed Jan 31, 2017 21:49 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | PurchaseCommon Stock | 16,666 | $15.00 | $249,990.00 |
DisclosureSEC source: 0001209191-17-006404 · doc4.xml · nonDerivative · entry 2 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,623 Read SEC document |
| January 31, 2017 Filed Jan 31, 2017 21:49 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | ConversionCommon Stock | 203,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-006404 · doc4.xml · nonDerivative · entry 1 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,957 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.